• Tue, August 9, 2022

Madhu Kumar Maintained (SNDX) at Strong Buy with Decreased Target to $35 on, Aug 9th, 2022

Madhu Kumar of Goldman Sachs, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Strong Buy with Decreased Target from $40 to $35 on, Aug 9th, 2022.

Madhu has made no other calls on SNDX in the last 4 months.



There are 2 other peers that have a rating on SNDX. Out of the 2 peers that are also analyzing SNDX, 0 agree with Madhu's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Madhu


  • Kalpit Patel of "B. Riley Securities" Initiated at Strong Buy and Held Target at $31 on, Thursday, July 28th, 2022
  • Edward White of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $31 on, Monday, April 11th, 2022